Zacks Investment Research on MSN
Is Gilead (GILD) a buy as Wall Street analysts look optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.
Zacks Investment Research on MSN
Here's why Gilead Sciences (GILD) is a strong value stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously administered treatment course.
Gilead Sciences, Inc.’s GILD Cell Therapy franchise currently comprises Yescarta and Tecartus. Sales from this unit decreased 7% year over year to $1.8 billion (in 2025) due to ongoing competitive ...
Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In. On ...
With no single news headline setting the tone, Gilead Sciences (GILD) has still given investors plenty to think about, as the ...
Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. US large-cap ...
Regeneron Pharmaceuticals stock increased by 19% over the past month driven by strong third-quarter earnings and robust sales of its flagship drugs, Dupixent (for eczema and other inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results